Abeona Therapeutics NASDAQ: ABEO expects treatment activity for its gene therapy ZEVASKYN to increase in 2027 as more qualified treatment centers begin treating patients, executives said during a fireside chat with Jefferies biotech analyst Maury Raycroft.
Chief Executive Vish Seshadri said the company’s immediate priority remains the launch of ZEVASKYN, which is approved to treat wounds in patients with recessive dystrophic epidermolysis bullosa, or RDEB. Abeona is also preparing to discuss a proposed late-stage trial for its recently added ABO-801 program with the Food and Drug Administration.
ZEVASKYN treatment centers and patient pipeline
Chief Commercial Officer Madhav Vasanthavada said eight qualified treatment centers are active, including four that have treated their first patients. Abeona aims for the other four centers to treat their first patients in the first half of 2027.
For the first half of 2027, the company is thinking about a cadence of roughly one patient per center per quarter, with some higher-volume centers treating more, Vasanthavada said. Seshadri said Abeona is working toward a double-digit treatment cadence by midyear.
Vasanthavada said operational hurdles, including insurance and coordination for patients traveling from another state, have been the main barriers at centers that have not yet treated a patient. Seshadri added that none of the eight centers is pausing and that each is processing paperwork for patients.
Abeona has identified more than 100 ZEVASKYN-eligible candidates, Vasanthavada said. Roughly 20% to 25% are active at a qualified treatment center, where prior authorization requests have been filed and patients have expressed interest in treatment. Most of the identified patients are still in the process of consulting their physicians.
Through the third quarter, Abeona had reported treating 15 patients, nine from the centers themselves and six referred from elsewhere, Vasanthavada said. He cautioned that the split does not necessarily indicate the future mix of referrals and existing center patients.
Asked about the mid-November to mid-January biopsy shutdown, Vasanthavada said the fourth and first quarters are shortened and that a couple of patients had moved from the fourth quarter into the first for health reasons. He said manufacturing was ongoing and the company would provide an update in early 2027.
Manufacturing and capacity plans
Executives said Abeona is working to reduce the risk of two types of manufacturing failures: a low-yield batch and a batch that fell outside specifications for a pan-CK identity test. Seshadri said each had occurred once in approximately 17 manufacturing runs.
The company is implementing manufacturing and assay improvements in consultation with the FDA to address low yield. For the identity test, Seshadri said Abeona is working with the agency on specifications based more heavily on real-world manufacturing experience. A Type C meeting is planned for the first quarter of 2027, and he expects meaningful updates on both issues in the first half.
Abeona is also preparing space to expand manufacturing capacity. Seshadri said the company could use two consecutive months of four patients as a potential trigger to hire for an increase from six to eight slots per month. He estimated a four- to six-month lead time, with a further increase to 10 slots potentially triggered by consecutive months at six patients.
At approximately six patients per month, gross margin could reach about 85%, Seshadri said, compared with the roughly 58% third-quarter figure cited by Raycroft. He said it could approach 90% at full capacity of 10 patients per month.
ABO-801 trial planning
Seshadri described ABO-801 as an oral formulation of fluticasone propionate designed for eosinophilic esophagitis, or EoE. He said two prior Phase 3 studies failed one co-primary endpoint based on patient-reported symptoms, but that Abeona’s analysis informed a revised trial design.
The company plans to seek FDA alignment in the first half of 2027 on a roughly 400-patient Phase 3 study with histology and swallowing-symptom co-primary endpoints at 12 weeks and a confirmatory secondary endpoint at 24 weeks. Seshadri said Abeona is proposing a different symptom questionnaire from the one used in the earlier studies.
He cautioned that the company’s post-hoc mapping between the questionnaires relies on assumptions and is “not a perfect science.” Asked whether Abeona had sufficient capital for the study and ZEVASKYN capacity expansion, Seshadri said yes, adding that substantial ABO-801 clinical spending was not anticipated until later in 2027.
Seshadri also pointed to partnered programs as potential catalysts. He said royalties and sales milestones from FAYUVI, which Abeona licensed to Ultragenyx and which is now approved, should begin in 2027. Taysha Gene Therapies expects FDA feedback on its planned submission for a Rett syndrome asset licensed from Abeona in the first half of 2027, he said.
About Abeona Therapeutics (NASDAQ:ABEO)
Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company's lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient's skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.